What is the best tech stack for a dermatology practice in 2027?

What a dermatology stack actually has to solve

A dermatology practice is not a primary-care clinic with a different specialty checkbox on the vendor order form. Four structural mechanics force a materially different stack, and every buying decision downstream traces back to one of them. Get these four wrong and no amount of feature shopping rescues the build.

The chart is a picture, not a paragraph. Dermatology is the most visual specialty in medicine. A single full-body skin check produces dozens of documented findings, each carrying an anatomic location, a morphology, a clinical or dermoscopic photo, and a disposition — watch, biopsy, treat, or refer. The chart has to anchor each of those to a body map and attach imagery to a specific site, not to the encounter generically. A generic SOAP-note EHR collapses under this load: charting twenty lesions as free text in a ten-minute slot is the difference between a provider seeing thirty-five patients a day and one seeing twenty. That throughput gap is the single largest financial variable in the entire stack, and it is decided by the EHR choice alone.

Three revenue lines bill three different ways under one roof. Medical dermatology — acne, psoriasis, eczema, skin-cancer screening — bills insurance on E/M and procedure codes. Surgical dermatology and Mohs micrographic surgery bill staged surgical codes with their own documentation and pathology requirements. Cosmetic dermatology — neuromodulators, fillers, lasers, chemical peels — is cash-pay, taxable in many states, and tracked by units and inventory rather than CPT. One patient can touch all three lines inside a single month. The stack must hold one clinical record while routing each service to the correct financial path, and must make cross-billing a cosmetic service to a payer structurally impossible rather than merely discouraged.

Dermatopathology is inside the workflow, not downstream of it. A large share of derm encounters end in a biopsy. That specimen must be labeled, tracked, routed to an internal or external dermpath lab, matched back to the correct patient and the correct anatomic site, and returned as a discrete result that triggers a callback, an excision, or a Mohs referral. A broken specimen-to-result loop is simultaneously a patient-safety event and a revenue leak — the excision that never gets scheduled is both. Practices in other specialties can treat lab as an interface nicety. In dermatology it is load-bearing.

Biologics and recall density define the back office. Modern medical derm leans heavily on biologics — dupilumab, IL-17 and IL-23 inhibitors — which require prior authorization, specialty-pharmacy routing, and copay-assistance tracking. Simultaneously, skin-cancer surveillance means unusually dense recall: annual and semi-annual skin checks that must be scheduled, reminded, and reactivated automatically or the practice quietly bleeds its highest-margin medical volume. Both loads land on the revenue-cycle and patient-engagement layers, which carry far more weight here than in a typical ambulatory practice.

The layers and what goes in each

Work the stack as layers, not as a shopping list. Each layer has one job, and the integration between adjacent layers matters more than any individual feature comparison.

Derm EHR and practice management — the spine. ModMed EMA (Modernizing Medicine) is the category default because it was built for dermatology rather than retrofitted: image-anchored encounters, native body map, Mohs mapping, lesion-level coding, and an integrated cosmetic module, with practice management and scheduling in the same product. Nextech is the strongest alternate when the practice is cosmetic-heavy and wants deeper aesthetic and inventory tooling. EZDerm is the value pick for solo and small groups wanting a derm-native, tablet-first chart without enterprise pricing. Budget roughly $600–$1,000 per provider per month for ModMed including PM; EZDerm lands materially below that. Generic ambulatory platforms can be forced to work, but they lack native lesion-level and Mohs workflows, and the throughput penalty is permanent.

Dermatopathology and lab integration. Whether the practice runs an in-house lab or sends out, the requirement is identical: bidirectional, specimen-level interfacing so results return as discrete data, not scanned PDFs. LigoLab is a strong laboratory information system for practices operating their own lab; reference labs such as PathGroup provide outbound routing and result delivery. ModMed and Nextech both offer path-result interfaces. Interface and LIS costs typically run $300–$2,000 per month depending on volume and ownership. The non-negotiable is a hard-stop worklist that keeps every outstanding biopsy visible until a result is filed and a disposition is recorded.

Cosmetic, point-of-sale, and inventory. The cash line needs its own commerce layer: point-of-sale, package and membership handling, consent capture, before-and-after photo storage, and unit-level inventory for neuromodulators and fillers. The ModMed cosmetic module keeps cosmetics in the same chart as medical derm — ideal for single-vendor practices. Aesthetic Record is the better standalone when the cosmetic side operates almost as a separate business, typically around $200–$400 per month. Manufacturer loyalty programs — Allē from Allergan, Aspire from Galderma — layer on top so patients bank rewards on Botox, Juvéderm, Dysport, and Restylane purchases.

Intake and patient payments. Phreesia handles digital pre-visit intake, insurance eligibility verification, consent capture, and patient-responsibility collection at or before check-in. That matters disproportionately in derm because one patient may owe an insurance copay and a cash cosmetic balance in the same visit. Pricing is typically per-provider-per-day or per-visit and scales with volume. Smaller practices can substitute the EHR's native intake plus a messaging tool to keep the vendor count down.

Engagement, messaging, and recall. Klara (now part of ModMed) covers two-way secure messaging, appointment reminders, and recall campaigns; Solutionreach is the alternate for practices on non-ModMed platforms. Budget roughly $300–$600 per month for a multi-provider practice. The return here is not messaging convenience — it is automated reactivation of lapsed annual skin-check patients, which is the highest-ROI marketing motion a derm practice has, because the patients already exist and already converted once.

Revenue cycle and clearinghouse. Derm billing is unusually error-prone: Mohs staging, biopsy and pathology code pairing, biologics, and the medical-cosmetic split all generate denial risk. ModMed BOOST is the integrated revenue-cycle service. Independent of the RCM choice, the practice needs a clearinghouse — Availity is often free at the basic claims tier, Waystar costs more but brings substantially richer denial management and analytics. Outsourced derm-specialty RCM firms typically charge 4–7% of collections; keeping billing in-house with a clearinghouse runs roughly $100–$1,000 per month in software depending on tier.

E-prescribing and prior authorization. E-prescribing including EPCS for controlled substances runs natively through the EHR via Surescripts. For biologics, electronic prior authorization through CoverMyMeds — frequently embedded directly in the prescribing flow and typically free to prescribers — replaces a multi-day fax cycle with a same-session submission. This is usually bundled into the EHR license and is one of the few genuinely low-cost, high-leverage pieces of the stack.

Accounting and business intelligence. A solo or small group runs QuickBooks Online at roughly $90–$200 per month with a bookkeeper who understands the three-line split. Multi-location groups and DSOs move to Sage Intacct for multi-entity consolidation and location-level P&L, starting around $15,000 per year. Power BI at roughly $10–$20 per user per month sits on top, and the reason it matters in derm specifically is the three-line split: leadership needs per-provider, per-location, and per-line margin, plus cosmetic attach rate and recall fill rate, and no single upstream system produces that view alone.

How the pieces connect end to end

The integration diagram is the actual deliverable of a stack decision — more than any vendor scorecard, it is what tells you whether the build will hold. Read it as three parallel financial paths sharing one clinical record, plus a lab loop that must close.

Three properties of this architecture are worth naming explicitly. First, the cosmetic branch never touches the clearinghouse — that separation is a deliberate structural control, not a billing preference, and it should be enforced in configuration rather than by staff discipline. Second, the path arrow is bidirectional: the specimen leaves and the discrete result returns to the same chart, and any design where results come back as unmatched PDFs has failed the requirement regardless of what the interface is called. Third, both the revenue-cycle layer and the cosmetic point-of-sale feed accounting and BI independently, because per-line margin is uncomputable if cash cosmetics only exist inside a payments processor the finance layer cannot see.

Sequence the build to match the diagram. Days 0–30 stand up the clinical core: EHR and PM, body map, lesion and Mohs templates, in-room photo capture, chart migration, provider and schedule configuration. Validate that a real high-volume skin check can be charted in the room, in real time, before moving on — if that fails, nothing downstream matters. Days 31–60 wire the financial layers: clearinghouse eligibility, claims and electronic remittance, e-prescribing and EPCS, biologics prior-auth routing, and the structural wall between cosmetic point-of-sale and claim generation. Days 61–90 turn on engagement and visibility: intake and patient payments, recall campaigns for annual skin checks, the dermpath interface with its hard-stop biopsy worklist, and the dashboards that report medical versus surgical versus cosmetic margin by provider and location.

What it costs at each size

Budget by practice shape, not by seat count alone, because the cosmetic and pathology lines drive cost independently of provider headcount.

Solo dermatologist, one provider, single location. EZDerm or entry-tier ModMed, digital intake and payments, a free-tier clearinghouse such as Availity, built-in or light messaging, QuickBooks Online, and outsourced or part-time revenue-cycle help. Roughly $1,500–$4,000 per month in software and services, plus per-collection RCM fees at the 4–7% range if outsourced. Deliberately omitted at this size: a data warehouse, an enterprise RCM contract, a standalone BI license, and a separate cosmetic platform. The goal is a derm-native chart, clean claims, and automated skin-check recall without back-office overhead.

Multi-provider group, three to fifteen providers, one to four locations. ModMed EMA or Nextech with the cosmetic module, messaging and recall, digital intake, an integrated dermpath interface, a Waystar-grade clearinghouse with denial analytics, cosmetic point-of-sale, reputation management at roughly $300–$500 per month, QuickBooks or early Sage Intacct, and either EHR-native dashboards or Power BI. Roughly $6,000–$25,000 per month all-in. This is the band where denial analytics starts paying for itself outright — at this claim volume a one-point improvement in denial rate is material against the incremental clearinghouse cost.

Dermatology DSO or large group, fifteen-plus providers, many locations. Enterprise derm EHR, centralized in-house dermatopathology with a full LIS, a centralized revenue-cycle operation, Sage Intacct multi-entity accounting, a data warehouse, and Power BI or Tableau for per-line, per-provider, per-location margin. Roughly $30,000–$200,000+ per month across software, lab operations, and centralized back office. At this scale the economics invert: the lab and the centralized billing operation dominate the budget and the software line becomes comparatively small, which is precisely why consolidation groups treat back-office centralization as the whole investment thesis rather than a support function.

On timelines, plan for 90 days to a working stack and roughly two quarters to steady-state throughput. Chart migration and template building are the long poles in the first month; denial-rate normalization after a billing cutover typically takes a full claims cycle plus one to observe honestly. Do not judge the RCM build on the first thirty days of remittance data — the sample is contaminated by cutover artifacts and will either panic you or falsely reassure you.

Where practices get this wrong

Cross-billing a cosmetic service to insurance. This is the most dangerous derm-specific error in the stack, and it is a compliance and audit exposure rather than a billing annoyance. It happens two ways: a cash cosmetic service gets routed to a payer, or a medical visit gets upcoded because a cosmetic add-on muddied the note. The fix is structural, not procedural. Configure the EHR so cosmetic service lines cannot reach claim generation at all, and reconcile cosmetic point-of-sale revenue against insurance claims monthly. If the control depends on a front-desk staffer remembering the rule, it will fail on a busy Friday.

A specimen-to-result loop with no hard stop. Biopsies sent out without tracking, results returning as unmatched PDFs, callbacks that never fire. Every one of those is a patient-safety event in waiting and a malpractice exposure, and the revenue consequence — the excision never scheduled — is almost beside the point. Require bidirectional, specimen-level interfacing and a worklist that keeps each outstanding biopsy blocking until a result is filed and a disposition recorded. Audit the open-biopsy list weekly with a named owner.

Forcing a generic EHR onto a derm practice. Usually driven by price or by inheritance from a parent organization. The practice saves on license cost and then watches providers slow from thirty-five patients a day to twenty because charting twenty lesions as narrative text takes too long. The visit-throughput difference dwarfs the license delta at almost any realistic volume. Choose derm-native up front; retrofitting after a year of accumulated charts is far more expensive than paying the premium on day one.

Letting skin-check recall go unautomated. Without automated reactivation of patients due for annual skin checks, a practice silently loses its steadiest, highest-margin medical volume — and the loss is invisible because nothing breaks and no one complains. Run recall campaigns from the engagement layer and track recall fill rate as a board-level metric, not a front-desk afterthought.

Splitting scheduling and clinical across vendors. Practices that vendor-split their scheduling and clinical workflows tend to end up rebuilding the billing stack later, because the seams between systems are exactly where claims fail. Weight integration depth above feature breadth when the two conflict, and budget for a consolidation move rather than being surprised by one.

Buying business intelligence too early. A single-location group with one revenue line gets enough from EHR-native dashboards and accounting reports. A warehouse and a BI license earn their keep once there are multiple locations or multiple revenue lines to compare. Buying BI before there is anything to compare produces expensive dashboards nobody opens.

Choosing between the options

The decision tree below resolves the majority of dermatology stack choices. Answer honestly about revenue mix — most practices overstate their cosmetic share when shopping and understate it when budgeting.

Four rules govern how to use that tree. First, decide the EHR before anything else and let it constrain the rest — the chart is the only layer whose replacement cost is measured in years, and every other component is comparatively cheap to swap. Second, do not shop the long tail. Weight integration depth above feature breadth and pick from the small set of genuinely derm-native platforms rather than evaluating thirty generic products on a spreadsheet. Third, buy the lab interface at the level your biopsy volume actually requires today, but require bidirectional discrete results at every tier, including the smallest — that requirement never relaxes with size. Fourth, defer BI and warehousing until there are at least two locations or two meaningful revenue lines to compare; before that, the EHR's native reporting plus a clean chart of accounts is genuinely sufficient.

Finally, watch the tells that a stack decision is drifting. If the vendor demo spends more time on cosmetic marketing features than on lesion charting speed, the product is aimed at a med spa rather than a dermatology practice. If nobody in the sales cycle can describe the specimen-tracking worklist in concrete terms, the pathology loop will not close. And if the billing configuration relies on staff remembering not to send cosmetic charges to a payer, the control does not exist — it only feels like it does.

Related questions

How is a dermatology stack different from a med spa stack?

A med spa is almost entirely cash-pay cosmetics: point-of-sale, memberships, inventory, and marketing dominate. Dermatology carries all of that on its cosmetic line but adds insurance-billed medical derm, staged surgical Mohs billing, dermatopathology, biologics prior authorization, and skin-cancer recall — so it needs a true clinical EHR and revenue-cycle spine underneath.

Can I run cosmetics on a completely separate system?

Yes, and cosmetic-heavy practices often do. The trade-off is that a standalone platform gives richer commerce tooling but splits the patient record, so before-and-after photos and consents live outside the medical chart. If you split, insist that both systems export cleanly to accounting so per-line margin remains computable.

What is the single most important metric to instrument first?

Recall fill rate for annual skin checks, followed closely by denial rate. Recall drives the steadiest high-margin medical volume and degrades invisibly when unautomated; denial rate tells you whether the three-line billing split was configured correctly. Both should be visible on a dashboard within the first 90 days.

Does an in-house dermatopathology lab change the stack?

Substantially. Owning the lab means adding a full laboratory information system with accessioning, specimen tracking, and bidirectional result delivery, plus the operational cost of running a lab. Send-out practices need only a reference-lab interface and a tracking worklist, which is materially cheaper and simpler to maintain.

How long before the stack reaches steady-state performance?

Plan 90 days to a functioning stack and roughly two quarters to stable throughput and denial rates. Chart migration and template building dominate the first month; billing metrics need a full claims cycle plus one before the data is clean enough to judge the revenue-cycle build honestly.

FAQ

Why is a derm-native EHR worth the premium over a generic ambulatory platform?

Because the throughput difference is permanent and compounding. Derm-native platforms anchor encounters to a body map, attach imagery to specific anatomic sites, support lesion-level coding, and include Mohs mapping — which is what lets a provider chart twenty findings inside a ten-minute visit. On a generic chart, the same visit becomes narrative text and the provider slows down. At realistic volumes the lost visits outweigh the license difference by a wide margin, and the gap does not close with training or customization.

Do I really need a dermatopathology interface, or can I just scan results in?

You need a real interface. Scanning PDFs breaks discrete-result reporting, makes trending impossible, and creates exactly the gap where biopsies get lost between collection and callback. The requirement is bidirectional, specimen-level interfacing plus a hard-stop worklist that keeps every outstanding biopsy visible until a result is filed and a disposition is recorded. This is a patient-safety control, not a reporting convenience, and it applies at every practice size including solo.

How do I keep cosmetic and medical billing from colliding?

Make it structural. Configure the EHR so cosmetic services follow a cash point-of-sale path that cannot reach claim generation, then reconcile cosmetic revenue against insurance claims monthly as a detection backstop. The largest compliance exposure in dermatology is a cosmetic charge accidentally hitting a payer, so this separation should be the first thing built during the billing configuration — before templates, before dashboards, before anything optional.

What does the biologics and prior-authorization workload actually require?

A clearinghouse with real-time eligibility plus an electronic prior-authorization path, typically embedded in the e-prescribing flow and supplemented by payer portals. Track copay-assistance enrollment and specialty-pharmacy routing inside the EHR so a biologics coordinator can manage the caseload from a worklist rather than a fax queue. The software cost here is low — often bundled or free to prescribers — while the labor savings on a growing biologics panel are substantial.

Is a data warehouse worth it for a single-location practice?

Usually not. A solo or small single-location group gets sufficient visibility from EHR-native dashboards plus accounting reports. A warehouse and a BI layer start earning their keep once there are multiple locations or multiple revenue lines to compare and leadership needs per-provider, per-location, per-line margin that no single upstream system can produce alone. Buying it earlier produces dashboards nobody opens.

What should I build first if I can only do one thing this quarter?

The clinical core — the derm-native EHR with body map, lesion templates, and in-room photo capture — validated against a real high-volume skin check charted in the room. Everything else in the stack hangs off that record. If the chart cannot keep up with the exam, no billing configuration, recall campaign, or dashboard fixes the underlying economics of the practice.

Sources

• https://www.modmed.com/ — Modernizing Medicine dermatology EHR, practice management, cosmetic module, and revenue-cycle documentation
• https://www.nextech.com/ — Nextech dermatology and aesthetic EHR/PM platform and inventory documentation
• https://www.ezderm.com/ — EZDerm dermatology-specific EHR and practice-management materials
• https://www.aad.org/member/practice — American Academy of Dermatology practice-management, Mohs, and dermatopathology guidance
• https://www.phreesia.com/ — Phreesia patient intake, eligibility verification, and point-of-service payments
• https://www.availity.com/ — Availity clearinghouse, eligibility, claims, and remittance documentation
• https://www.waystar.com/ — Waystar revenue-cycle, claims, and denial-management platform documentation
• https://surescripts.com/ — Surescripts e-prescribing and EPCS network documentation
• https://www.covermymeds.com/ — CoverMyMeds electronic prior-authorization platform documentation
• https://www.ligolab.com/ — LigoLab laboratory information system and pathology workflow documentation

Related on PULSE

• [What is the best tech stack for a podiatry practice in 2027?](/knowledge/tk0111)
• [What is the best tech stack for an audiology or hearing aid practice in 2027?](/knowledge/tk0110)
• [What is the best tech stack for an orthodontics practice in 2027?](/knowledge/tk0102)
• [The Essential Software Stack for a Modern Veterinary Practice](/knowledge/tk0346)
• [The Veterinary Practice Management Stack in 2027](/knowledge/tk0487)
• [Top 10 Legal Practice Management Software for Solo Lawyers](/knowledge/tk0431)